logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Editorial

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A,  et al.
2025-03-01 • IJTLD OPEN
2025-03-01 • IJTLD OPEN

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...

Journal Article
|
Research

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Khan U, Rich M, Franke M, Lachenal N, Ahmed S,  et al.
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Journal Article
|
Research

Management of Chronic Hepatitis C at a Primary Health Clinic in the High-Burden Context of Karachi, Pakistan

Capileno YA, Van der Bergh R, Donchunk D, Hinderaker SG, Hamid SS,  et al.
2017-04-27 • PLOS One
2017-04-27 • PLOS One
The burden of hepatitis C (HCV) infection in Pakistan is among the highest in the world, with a reported national HCV prevalence of 6.7% in 2014. In specific populations, such as in urba...